Chase is a Research Analyst at Fisher Investments and has been with the firm since 2013.
By Chase Arneson, 09/25/2015
Capping prescription drug prices would be a negative for the industry, but even if the idea became legislation, it isn't likely to pass through the political gauntlet.No articles found.